Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Refractory Gastric or Gastroesophageal Adenocarcinoma
NCT01757171Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2012
- Primary completion
- Jul 2016
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in gastric adenocarcinoma, gastroesophageal adenocarcinoma, distal esophageal adenocarcinoma, sponsored by Weill Cornell Medicine. Started Dec 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinomadistal esophageal adenocarcinoma
Beyond the preview
Go deeper on NCT01757171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757171.